DRTSW NASDAQ
Alpha Tau Medical Ltd.
1W: +7.3%
1M: -13.7%
3M: +54.6%
YTD: +856.8%
1Y: +807.7%
3Y: +785.0%
$3.54
+0.54 (+18.00%)
Weekly Expected Move ±18.4%
$2
$3
$3
$4
$4
Credit Risk of going bust: lower than 70% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down 99.9%), Alpha Tau Medical Ltd. would be worth roughly what it owes.
Total debt $15.2M against a stock market value of $1.25B.
Distance to default 7.56 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 75.2%; Altman Z'' -3.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $15.2M against a stock market value of $1.25B.
Distance to default 7.56 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 75.2%; Altman Z'' -3.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range0.28-4.62
Volume4,375
Avg Volume62,717
Beta1.19
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOUzi Sofer
Employees112
SectorHealthcare
IndustryBiotechnology
IPO Date2026-03-06
Websitealphatau.com
Kiryat HaMada St. 5
Jerusalem, JM 9777605
IL
Jerusalem, JM 9777605
IL
972 3 577 4115
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
Latest News
Alpha Tau Medical Ltd. Estimates – NASDAQ:DRTSW - TradingView
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Average Price Target of $15.40 According to Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 15,527 | $6.41 | 2026-03-18 | |
| KIDRON NADAV | 0 | — | 2026-03-18 |